Literature DB >> 33312390

LINC01305 inhibits malignant progression of cervical cancer via miR-129-5p/Sox4 axis.

Yuexun Xu1, Haiyan Zhu2, Hongbin Ma3, Lei Yuan4, Qunchao Hu5, Liang Yang5.   

Abstract

BACKGROUND: The association between LINC01305, a newly discovered long non-coding RNA (lncRNA), and cervical cancer (CC) has been poorly analyzed. In the present study, we revealed high expression of LINC01305 in CC by the cancer genome atlas (TCGA) and Gene Expression Omnibus (GEO), and dissected the related mechanisms.
METHODS: LINC01305, microRNA (miR) -129-5p and SRY-related high-mobility group box 4 (Sox4) mRNA levels were quantitated by quantitative reverse transcription-PCRy qRT-PCR). CC tissues and cell lines and corresponding controls were enrolled for the quantification of LINC01305 expression in CC. Effects of LINC01305 and miR-129-5p on cell proliferation, metastasis, and apoptosis were evaluated by MTT, colony formation, wound healing, Transwell and flow cytometry assays. Sox4 protein levels were tested by Western blot (WB). Bioinformatics analysis, RNA immunoprecipitation (RIP), RNA pull-down and dual-luciferase reporter (DLR) assay were performed to determine molecular mechanisms of LINC01305 in CC. Xenograft models of CC were constructed to evaluate the role of LINC01305 in vivo.
RESULTS: The expression of LINC01305 was evidently elevated in CC tissues and cell lines than that in controls and associated with clinicopathological features. Downregulating LINC01305 suppressed malignant phenotypes (proliferation, migration, invasion) of Hela and SiHa cells. In addition, silencing miR-129-5p by its inhibitor eliminated the inhibition of growth and metastasis induced by LINC01305 siRNA. Sox4 might serve as a direct target for miR-129-5p and was negatively regulated by miR-129-5p and LINC01305.
CONCLUSION: LINC01305 acts as a competitive endogenous RNA (ceRNA) and regulates Sox4 via sponging miR-129-5p, contributing to the diagnosis and treatment of CC. AJTR
Copyright © 2020.

Entities:  

Keywords:  Sox4; cervical cancer; lncRNA LINC01305; miR-129-5p

Year:  2020        PMID: 33312390      PMCID: PMC7724335     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  5 in total

1.  Functional Screen for microRNAs Suppressing Anchorage-Independent Growth in Human Cervical Cancer Cells.

Authors:  Angelina Huseinovic; Annelieke Jaspers; Annina P van Splunter; Hanne Sørgård; Saskia M Wilting; Dorian R A Swarts; Ida H van der Meulen; Victor W van Beusechem; Renée X de Menezes; Renske D M Steenbergen
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

2.  Identification of HOXD10 as a Marker of Poor Prognosis in Glioblastoma Multiforme.

Authors:  Yanxin Li; Ke Ma; Qi Xie; Xianwei Zhang; Xiulei Zhang; Kui Chen; Lingfei Kong; Rongjun Qian
Journal:  Onco Targets Ther       Date:  2021-10-27       Impact factor: 4.147

3.  lncRNA PCGEM1 Regulates the Progress of Colorectal Cancer through Targeting miR-129-5p/SOX4.

Authors:  Bingsheng Guan; Fazhi Chen; Zhenpeng Wu; Cunchuan Wang; Jingge Yang
Journal:  Dis Markers       Date:  2022-09-20       Impact factor: 3.464

4.  BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.

Authors:  Kathleen Gebhardt; Bayram Edemir; Elisabeth Groß; Linda Nemetschke; Stefanie Kewitz-Hempel; Rose K C Moritz; Cord Sunderkötter; Dennis Gerloff
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

5.  Activation of FGD5-AS1 Promotes Progression of Cervical Cancer through Regulating BST2 to Inhibit Macrophage M1 Polarization.

Authors:  Guokun Liu; Xuan Du; Li Xiao; Qing Zeng; QianLing Liu
Journal:  J Immunol Res       Date:  2021-10-15       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.